KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Tax Provisions (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Tax Provisions for 8 consecutive years, with -$137000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 59.3% to -$137000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $217000.0 through Dec 2025, up 118.95% year-over-year, with the annual reading at $217000.0 for FY2025, 118.95% up from the prior year.
  • Tax Provisions hit -$137000.0 in Q4 2025 for Vir Biotechnology, down from $168000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $403.3 million in Q1 2022 to a low of -$157.2 million in Q2 2022.
  • Historically, Tax Provisions has averaged $12.3 million across 5 years, with a median of $34500.0 in 2021.
  • Biggest YoY gain for Tax Provisions was 205658.16% in 2022; the steepest drop was 296756.6% in 2022.
  • Year by year, Tax Provisions stood at $20.6 million in 2021, then plummeted by 342.48% to -$50.0 million in 2022, then soared by 90.44% to -$4.8 million in 2023, then surged by 98.2% to -$86000.0 in 2024, then crashed by 59.3% to -$137000.0 in 2025.
  • Business Quant data shows Tax Provisions for VIR at -$137000.0 in Q4 2025, $168000.0 in Q3 2025, and $170000.0 in Q2 2025.